Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research

Myriad Genetics (NASDAQ:MYGN) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other equities analysts have also issued reports about the company. UBS Group dropped their price objective on Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a research report on Monday, December 29th. Piper Sandler reduced their price objective on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. TD Cowen restated a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company dropped their target price on shares of Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.17.

Myriad Genetics Stock Performance

Shares of Myriad Genetics stock traded down $0.25 on Thursday, reaching $4.61. The stock had a trading volume of 2,121,107 shares, compared to its average volume of 1,356,845. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.12 and a current ratio of 2.49. The business’s 50-day moving average price is $5.61 and its two-hundred day moving average price is $6.59. The stock has a market cap of $431.08 million, a P/E ratio of -1.17 and a beta of 1.90. Myriad Genetics has a fifty-two week low of $3.76 and a fifty-two week high of $11.44.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Monday, February 23rd. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.06. The firm had revenue of $209.80 million for the quarter, compared to the consensus estimate of $207.57 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $0.03 EPS. On average, sell-side analysts forecast that Myriad Genetics will post -0.3 EPS for the current year.

Insider Activity

In other news, Director S. Louise Phanstiel bought 48,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $4.66 per share, for a total transaction of $223,680.00. Following the completion of the purchase, the director owned 281,951 shares of the company’s stock, valued at $1,313,891.66. This trade represents a 20.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased 104,507 shares of company stock worth $494,548 in the last quarter. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Myriad Genetics

Several institutional investors and hedge funds have recently bought and sold shares of MYGN. EverSource Wealth Advisors LLC lifted its holdings in shares of Myriad Genetics by 2,333.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after acquiring an additional 4,480 shares during the period. Quarry LP increased its stake in Myriad Genetics by 155.6% in the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after acquiring an additional 2,657 shares during the period. Hantz Financial Services Inc. raised its position in Myriad Genetics by 1,088.7% in the third quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company’s stock worth $30,000 after purchasing an additional 3,745 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Myriad Genetics by 407.3% during the second quarter. Nisa Investment Advisors LLC now owns 5,773 shares of the company’s stock worth $31,000 after purchasing an additional 4,635 shares during the period. Finally, Royal Bank of Canada boosted its holdings in Myriad Genetics by 129.6% during the fourth quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after purchasing an additional 2,818 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics News Summary

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Director S. Louise Phanstiel completed multiple open‑market purchases across Feb. 25–27 totaling roughly 104,507 shares (average prices ~$4.66–$4.80) and materially increased her stake — a strong insider-confidence signal that can attract buyers. SEC Form 4 filing
• Positive Sentiment: Zacks upgraded MYGN from “strong sell” to “hold,” which may reduce model-driven selling and ease some downward pressure from quant/algorithmic strategies. Zacks.com
• Neutral Sentiment: Media coverage amplified the insider activity (TipRanks/MarketBeat coverage), likely increasing short-term volume and retail interest but not changing fundamentals by itself. TipRanks article
• Negative Sentiment: Management updated Q1 FY2026 guidance with revenue of $200.0M–$203.0M versus consensus ≈ $203.5M and provided no EPS figure — the slightly light top‑line range and missing EPS guidance increase uncertainty and can pressure the stock if focus shifts to short‑term weakness.
• Negative Sentiment: Several Wall Street firms have trimmed targets or maintained cautious ratings recently (e.g., UBS, Wells Fargo reductions), reinforcing mixed analyst sentiment and limiting near‑term upside until fundamentals or outlook materially improve.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.